SOHM (OTC: $SHMN) has achieved a significant breakthrough in gene editing technology with its proprietary ABBIE platform version 2. The company successfully demonstrated that its advanced dCas12a domain can effectively modify human cells, enabling multi-target editing capabilities through crRNA arrays.
https://stocktitan.net/news/SHMN/sohm-achieve...tmoe4.html